U.S., March 27 -- ClinicalTrials.gov registry received information related to the study (NCT06895031) titled 'Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS' on March 19.
Brief Summary: Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.
Study Start Date: March 27
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Pancreatic Ductal Adenocarcinoma (PDAC)
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Intervention:
DRUG: JYP0015
JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms. The drug will be administered orally,...